MTATP6P7

Across TCGA pan-cancer cohorts, MTATP6P7 RNA is linked to patient survival in 9 of 34 cancer types, making it the most broadly survival-associated MTATP6P7 data layer.

The strongest signal is observed in uterine carcinosarcoma (UCS), where higher MTATP6P7 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated MTATP6P7 expression acts as an unfavorable survival marker.

UCS, KIRC, and CHOL are the cancer types where MTATP6P7 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCS	OS	Tertile	II,III,IV	0.068	0.631	<.001	108	view →
KIRC	DFS	Tertile	II,III,IV	0.176	0.663	.001	90	view →
CHOL	OS	Tertile	All	0.019	0.800	<.001	72	view →
OV	DFS	Tertile	All	0.254	0.389	.015	54	view →
PAAD	OS	Tertile	II,III,IV	0.210	0.556	.007	36	view →
LUAD	OS	Tertile	III,IV	0.223	0.663	.034	27	view →
LIHC	OS	Tertile	III,IV	0.195	0.648	.013	18	view →
PRAD	DFS	Tertile	All	0.186	0.779	.003	18	view →
HNSC	OS	Tertile	III,IV	0.174	0.673	.048	9	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

MTATP6P7–UCS (OS)

Open the UCS breakdown →